来源 | 《财经》杂志 作者 | 《财经》记者 凌馨 编辑 | 王小 超跌之后的估值回归，是造就"X倍股"的最大因素 中国医药股领涨全球的2025年，涨幅最高的个股有哪些？ 香港市场，涌现出一批"三倍股""四倍股"，甚至"十倍股"，其中，有因产品海外授权交易声名鹊起的和铂医药、荣昌生物，也有2025年踩中了港股医药热点 的"打新宠儿"，还有一批，是经历了上一轮寒冬后，终于等来投资市场春天的老牌未盈利药企。 北海康成曾是"中国罕见病第一股"。它的产品，都是治疗普通人几乎没听说过的病。已经上市的两款产品，分别用于治疗黏多糖贮积症Ⅱ型、阿拉杰里综合 征以及进行性家族性胆汁淤积症。 因为主要针对罕见病市场，北海康成的产品市场都很小。2021年就在中国市场推出的首款产品，是用于治疗黏多糖贮积症Ⅱ型，至2024年末，共识别出843 名患者。另一款已上市产品，识别患者数为839名。 理论上，罕见病用药单价高，还可以享受药审、医保的各种政策倾斜，实际上，北海康成多年来仍处于亏损状态。2024年，全年收入8510.3万元，亏损金额 4.43亿元。截至2024年末，公司流动性资产4535.2万元，流动性负债4.826亿元。 北海 ...

Core Viewpoint - Despite forecasting a net loss for 2025, the company shows signs of steady improvement in its fundamentals through various operational and financial strategies [1][2]. Group 1: Financial Performance and Strategy - The company has experienced steady recovery in its business, with two consecutive quarters of revenue growth and three consecutive quarters of positive cash flow from operating activities [2]. - A syndicated loan of up to 10.2 billion yuan has been secured to optimize working capital and reduce debt pressure, alongside the issuance of technology innovation bonds to further enhance its financial structure [2]. - The optimization of marketing strategies and debt structure has improved short-term operational efficiency and cash flow, while also providing a solid financial foundation for long-term R&D and market expansion [2]. Group 2: Product Pipeline and Innovation - The company has a robust pipeline with 34 projects in the preventive biological products sector, of which 24 are in clinical trials or application stages, including two newly approved influenza vaccines [3][4]. - The treatment biological drugs sector is positioned as a new growth engine, with multiple projects focusing on metabolic diseases, including insulin analogs and GLP-1 receptor agonists, showing significant progress [4]. - The company has invested over 6 billion yuan in R&D over the past three years, establishing a strong foundation for talent, technology breakthroughs, and product innovation [5]. Group 3: Talent and R&D Infrastructure - The company has built a high-quality professional R&D team and established an innovation incubation center in Beijing, collaborating with top universities and research institutions [6]. - Three major R&D and production bases have been established in Beijing, Anhui, and Chongqing, focusing on different vaccine types and treatment products, enhancing the company's innovation capabilities [6]. Group 4: Global Expansion and Market Presence - The company is actively pursuing internationalization, conducting clinical trials for innovative products overseas, and has initiated trials for a dual-valent vaccine in Bangladesh [8]. - It has successfully supplied vaccines to countries like Indonesia and Nigeria, and is working on global registration for tuberculosis diagnostic products [9]. - Participation in international pharmaceutical exhibitions enhances the company's global brand presence and facilitates future business expansion [9]. Group 5: Commitment to Innovation and Quality Development - The company emphasizes innovation-driven development, aiming to transition from following to leading in the biopharmaceutical industry, aligning with national policies that support source innovation [10].

Core Viewpoint - The article emphasizes the challenges faced by chronic obstructive pulmonary disease (COPD) patients during winter, particularly the "Nine Cold Days" period, and outlines strategies for effective self-management to navigate this season safely [2][3]. Group 1: Winter Challenges for COPD Patients - COPD patients account for over 30% of hospitalizations due to acute exacerbations of respiratory diseases in winter [2] - Cold air can trigger bronchospasm and increase respiratory resistance, while viruses and air pollution are more prevalent during this season [2] Group 2: Treatment Strategies - The latest treatment approach recommends early use of dual bronchodilators (LAMA+LABA) and triple therapy with inhaled steroids for patients with a history of exacerbations [3] - Patients should carry rescue medications but should seek medical advice if they need to use them more than twice a week, indicating insufficient maintenance therapy [3] Group 3: Immunization and Oxygen Therapy - Vaccination is crucial for preventing infections that can lead to acute exacerbations, with recommendations for flu, pneumococcal, shingles, and Tdap vaccines [4] - Long-term home oxygen therapy is essential for patients with chronic respiratory failure, and it should be used during daily activities to improve overall function [4] Group 4: Recognizing Early Signs of Exacerbation - Patients should learn to identify early signs of exacerbation, such as increased cough, sputum changes, and difficulty breathing, and monitor objective indicators like oxygen saturation [5][6] - Immediate action is advised if any signs of exacerbation occur, as timely intervention is critical for preserving lung function [6] Group 5: Lifestyle and Emotional Well-being - Keeping warm and wearing masks outdoors are essential for respiratory protection, along with maintaining a suitable indoor environment [7] - Emotional health is also important; social interactions and seeking professional help for persistent anxiety or depression can enhance treatment adherence and overall well-being [8]

Core Insights - GSK emphasizes its commitment to health management through a combination of prevention and treatment, showcasing its innovative product pipeline at the 2025 China International Import Expo [1][3][6] Group 1: Innovation and Product Pipeline - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for chronic hepatitis B that aims for "functional cure" [1][3] - The company also introduced a long-acting monoclonal antibody for chronic diseases and a first-in-class antibody-drug conjugate for multiple myeloma, covering various therapeutic areas [1][3] Group 2: Health Management Strategy - GSK is focused on integrating prevention and treatment, aiming to create a comprehensive health management model that spans the entire lifecycle of diseases [3][4] - The company has a long history in hepatitis management, providing innovative solutions from vaccines to antiviral treatments [3] Group 3: Collaboration and Market Strategy - GSK has established partnerships with local companies to enhance the accessibility of its vaccines and support healthcare initiatives in China [5] - The company plans to accelerate its local market strategy, with over 80% of its R&D projects in China aligned with global development, aiming to introduce approximately 18 new products and indications in the next three years [6]

Core Viewpoint - The 8th China International Import Expo (CIIE) showcased GSK's commitment to the Chinese market with its innovative health solutions, particularly highlighting the newly approved shingles vaccine, which targets high-risk groups [1][2][3]. Group 1: GSK's Vaccine Innovations - GSK's shingles vaccine, Xinanlis, is the first and only shingles vaccine approved by the NMPA for high-risk adults aged 18 and above [1][3]. - The vaccine's approval for expanded indications aims to protect individuals with immune deficiencies or immunosuppression, reflecting a shift towards proactive immunization across all life stages [1][3]. - GSK emphasizes the integration of vaccine prevention into chronic disease management, particularly for high-risk groups such as those with hypertension, diabetes, and cardiovascular diseases [2][3][11]. Group 2: Market Potential and Growth - The adult vaccine market in China is projected to grow significantly, with the shingles vaccine market expected to reach 5.63 billion yuan by 2025 and exceed 10 billion yuan by 2031 [9]. - With over 500 million chronic disease patients in China, achieving a 5% to 10% vaccination rate could translate to a market size in the hundreds of billions [9][10]. - The increasing prevalence of chronic diseases and an aging population are key drivers for the growth of the adult vaccine market [9]. Group 3: Challenges and Strategies - Despite high awareness of shingles (80%-90%) and vaccine knowledge (60%-80%), the vaccination rate remains low at 1%-2% [5]. - GSK is addressing this "knowledge-action gap" by implementing "vaccine prescriptions" to enhance accessibility and conversion rates for vaccinations [5][6]. - The company is developing a multi-tiered adult vaccine management system, aiming to integrate vaccine management with chronic disease management [6][10]. Group 4: Future Directions - GSK plans to extend its focus from cardiovascular and diabetes management to include other chronic diseases like COPD, promoting a comprehensive approach to disease management [12]. - The company is committed to leveraging its innovative research and development capabilities to enhance public health in China, particularly through the introduction of new vaccines [12].

Core Insights - GSK showcased its commitment to health management at the 8th China International Import Expo with the theme "Collaborate to Surpass, Create a Healthy Future" [1] - The company emphasizes a shift from disease-centered to health-centered pharmaceutical innovation, aligning with China's "Healthy China" initiative [1][2] - GSK presented several innovative products, including the world's first approved RSV vaccine and a drug for functional cure of chronic hepatitis B [1][2] Group 1: Product Innovations - GSK introduced a range of innovative pipeline products, including the first RSV vaccine approved globally and a long-acting drug for chronic hepatitis B [1] - The company also highlighted the first antibody-drug conjugate for multiple myeloma and a long-acting treatment for HIV [3] - GSK's new shingles vaccine is the first approved for adults with immunodeficiency due to known diseases or treatments [2] Group 2: Strategic Collaborations - GSK is collaborating with Hengrui Medicine to develop up to 12 innovative drugs across various therapeutic areas [3] - The company aims to deepen its local market presence with a strategy focused on speed, direction, and priority [3] - Over 80% of GSK's R&D projects in China are now integrated into global development, with approximately 18 new products expected to be approved in the next three years [3]

Group 1: Event Overview - The 8th China International Import Expo (CIIE) is held from November 5 to 10 at the National Exhibition and Convention Center in Shanghai [1] - The event showcases 461 new products, technologies, and services, transforming into a global stage for innovation [2] Group 2: Medical and Health Innovations - The medical device and healthcare exhibition area features significant innovations, including Siemens Healthineers' brain-machine interface solution, which integrates advanced imaging and navigation technologies [3] - Sanofi's innovative drug, Tregalizumab, for delaying the progression of Type 1 diabetes, has been approved in China after its debut at the expo [4] - Abbott presents over ten innovative products, including a dynamic blood glucose monitoring system that meets international standards [5] Group 3: Pharmaceutical Developments - GSK introduces several groundbreaking products, including the first approved RSV vaccine and a long-acting treatment for chronic hepatitis B [6] - EssilorLuxottica showcases new products for myopia management and wearable devices, emphasizing innovation in vision health [7] Group 4: Life Sciences and Technology - Illumina presents new solutions for protein detection and gene sequencing, highlighting advancements in life sciences [8][9] - The company emphasizes local manufacturing and partnerships to enhance its technological capabilities in China [8] Group 5: Consumer Goods and Sustainability - LEGO Group unveils five globally launched products inspired by Chinese culture, focusing on sustainability and creativity [10][11] - Kao's freeplus brand showcases its research in amino acid-based skincare, aiming to deepen its market presence in China [11] Group 6: Market Strategies and New Products - Skechers uses the expo as a strategic platform for launching new sports products, reinforcing its commitment to the Chinese market [12][13] - Ausnutria presents 61 products across various nutritional categories, emphasizing innovation and market responsiveness [14]

Core Insights - The 8th China International Import Expo (CIIE) is being held from November 5 to 10 in Shanghai, showcasing 461 new products, technologies, and services, transforming into a global stage for innovation [1] Industry Highlights - The medical device and healthcare sector is highlighted as the most innovative, with major companies unveiling cutting-edge products, including Siemens Healthineers' brain-computer interface solution, which integrates advanced imaging and navigation technologies for surgical applications [3][5] - Sanofi's innovative drug, Trelagliptin, is the first to delay the progression of Type 1 diabetes, having received approval from China's National Medical Products Administration (NMPA) [5] - Abbott presents over ten innovative products, including cardiovascular and diabetes management solutions, emphasizing the importance of chronic disease management [7][9] - GSK introduces several groundbreaking products, including the first approved RSV vaccine and a long-acting treatment for chronic hepatitis B [9] - EssilorLuxottica showcases innovative products for vision health, including smart glasses and advanced myopia management solutions [10][19] Company Innovations - Skechers uses CIIE as a platform for launching new sports products, including various footwear models, demonstrating the brand's commitment to the Chinese market [20][22] - Ausnutria presents 61 products across six imported brands, focusing on innovative nutritional solutions for different life stages, including the launch of new probiotic products [23]

Group 1: GE Healthcare and Alibaba - GE Healthcare signed a cooperation framework agreement with Alibaba's Damo Academy to integrate the "one scan, multiple checks" AI technology into advanced imaging equipment [1] Group 2: Nissan and Automotive Industry - Nissan established a joint venture, Nissan Import and Export (Guangzhou) Co., marking the first joint venture for foreign car manufacturers in China [2] - The first products to be exported from China include the Dongfeng Nissan N7 and Frontier Pro PHEV [2] Group 3: E-commerce and Retail - Taobao Flash Sale launched a program to provide new uniforms for 1 million active delivery riders, enhancing their equipment experience [3] - Huawei's 3,000 stores across 247 cities joined Taobao Flash Sale, offering rapid delivery services with a week-on-week sales increase of 1910% [5] Group 4: Aviation Industry - China Southern Airlines Group signed 23 import procurement agreements with a total value exceeding $2 billion, setting a new high in six years [7] - Cathay Pacific announced a buyback of shares from Qatar Airways, totaling approximately HKD 6.97 billion for 643,076,181 shares [4] Group 5: Pharmaceuticals and Healthcare - GlaxoSmithKline showcased multiple innovative vaccines and drugs at the China International Import Expo, including the first RSV vaccine approved for market [6] Group 6: Technology and AI - iFlytek launched a new multimodal digital human guide named "Xiao Fei," capable of multi-person dialogue and personalized memory [10] - iFlytek also released the Spark X1.5 deep reasoning model, achieving over 93% efficiency compared to international competitors [10] Group 7: Investment and Financing - Wireless Logic secured €2 billion in private equity funding, with a valuation of approximately £3.5 billion [9] - Ares Management Corp. is seeking to enhance its credit business in the Asia-Pacific region by recruiting a partner-level executive [9]

Core Insights - GSK's participation in the China International Import Expo (CIIE) highlights its commitment to innovation and collaboration in the healthcare sector, showcasing multiple groundbreaking products and partnerships [1][2] Group 1: Product Innovations - GSK presented several innovative pipeline products at the CIIE, including the world's first approved respiratory syncytial virus (RSV) vaccine and a novel antisense oligonucleotide (ASO) drug for chronic hepatitis B, which aims for functional cure [1] - The company also introduced the first antibody-drug conjugate for multiple myeloma and a long-acting monoclonal antibody that allows for administration every six months [1] - Previously showcased products, such as the recombinant shingles vaccine and new indications for the monoclonal antibody, were also featured at this year's expo [1] Group 2: Local Collaborations - GSK has been actively expanding local partnerships in China, collaborating with Zhifei Biological Products to enhance the accessibility of the shingles vaccine and with Hengrui Medicine to co-develop up to 12 innovative drugs across various therapeutic areas [1] - Over 80% of GSK's R&D projects in China are now integrated into global development efforts, focusing on prevalent diseases like chronic hepatitis B and major public health issues [2] - The company anticipates approximately 18 new products and indications to be approved in China within the next three years [2]